OBI Pharma is developing novel therapeutic agents
for unmet medical needs.
OBI Pharma Announces Discontinuation of the Phase 1/2 Study of its Antibody- OBI 888 to focus on other priority Cancer programs
OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced discontinuation of the Phase 1/2 Study* for OBI 888, a Globo H antibody, upon completion of enrollment in our investigative sites. “We are pleased that the preliminary data from our Phase 1/2 study demonstrated that OBI 888 is a safe …
Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, and OBI-3424
Title: A phase 3, randomized, open-label study of the anti-Globo H vaccine Adagloxad Simolenin/OBI-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer. Poster / Abstract number: TPS611 Title:First-in-Human Study of OBI-999: a Globo H-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors Poster / Abstract …
OBI Pharma Announces Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, OBI-3424, and Exhibition Booth
Poster Presentations to highlight the ongoing clinical studies targeting Globo H and AKR1C3 OBI Pharma, Inc. (TPEx: 4174), a leader in First-in-Class Cancer therapeutics, today announced that data highlighting ongoing clinical studies targeting Globo H and AKR1C3 in different tumor types will be presented at the American Society of Clinical …